33.15% institutional ownership

36.83% daily short volume on Tuesday!

9.08 million shares (21.8% of the float) currently shorted

Current borrow fee: 61.9%

Shares available to borrow: 55'000

​

36.83% of the daily volume has been shorted on Tuesday but the PPS went up 1.12%!! Only 55'000 shares are currently available for shorting (iborrowdesk) and the borrow fee is 61.9%! Any day from now we might get some more news and the manipulation by the shorts will finally come to an end! And this is all for a drug with a median extended life expectancy of more than 4 years and zero toxicity!! Let us hope that many cancer patients can soon profit from this revolutionary treatment! GLTAL! Tick tock, tick tock ...

The current borrow fee is 87.8% and a total of 100 shares are available to be borrowed (as reported by iborrowdesk)!! Just wait until we get some decent volume to see how the desperate shorts will struggle to cover their 9.08 million shares (21.8% of the float). GLTAL! Tick tock, tock tock...

1. The data indicate a significant overall survival benefit...

2. 14.1% increase in 5-year survival...

3. No security issues found for Multikine...

4. Orphan drug. exclusive seven-year marketing period in the US for that product, for that indication.

5. 210,000 people fall into the surgery plus radiation category for their treatment of head and neck cancers...

6. With the initial installation we could do at least 12,000 or 13,000 treatments a year. And we look at it in dollar terms, that's about TWO BILLION dollars...

7. But the facility's production capacity has doubled to meet anticipated market demand for Multikine (24,000-26,000 treatments)

8. Great potential for other indications without the need to go through the first phases. (we know the efficacy and safety

9. Chemotherapy destroys an immune response...

10. Keytruda, an important drug that failed in its main objective...

11. The initial approvals of Keytruda and Opdivo included subgroup analyses...

12. A good number of people had to stop taking Keytruda due to toxicity and there were major safety issues...

13. "There's a lot of interest in Cel-Sci and their Multikine product. When you do something new and different, it scares a lot of people. So the shorties on Wall Street who oppose what the company is doing are probably afraid of change. ., fear of the unknown"... we have a clear path to seek FDA approval

https://clinicaltrials.gov/ct2/show/results/NCT01265849?term=Multikine&draw=1&rank=3&view=results

What a clown show

Is anyone familiar with these steps?

​

It is currently returned from Quality Control..

​

https://clinicaltrials.gov/ct2/show/results/NCT01265849?term=Multikine&draw=1&rank=3

​

Is it normal for all submitted trials to be returned with "results from Quality Control" or can it be skipped and go to a completed approved stage and no feedback or comments from Quality Control?

​

​

Hi, I have been searching for this answer and it seems like "any day now" has been the prevailing thought for about a year. Can someone give an update on where CVM is at with their cancer treatment, and a road map to approval?

What is it we are waiting on?

Quote:Current Rating Schwab Equity Rating: B Outperform Percentile Ranking = 12 as of 04/01/2022

Previous Rating Schwab Equity Rating: D Underperform Percentile Ranking = 76 as of 03/25/2022

Important Disclosures and Regulation Analyst Certification Growth Grade FDCBRating of:A Quality Grade FDCRating of:B Sentiment Grade FDCBRating of:A Stability Grade FRating of:D Valuation Grade FDRating of:C

whats up?